Interface Biosciences
Interface Bio develops next-generation, multi-targeted immunotherapies by integrating human biology and Artificial Intelligence. The company leverages a platform that mines natural product chemical scaffolds from commensal microbes for therapeutic development. This approach aims to generate safe and effective drug candidates for complex diseases like cancer and autoimmune disorders at an accelerated rate.
- Artificial Intelligence
- Biotechnology
Funding
Raised to date
$5.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$3M across 1 disclosed round
+2$3M · Seed
Announced Dec 2023
Disclosed cumulative: $3M
Reported total $5.2M
Incomplete round history. $2.2M of the $5.2M reported total isn’t matched to a known round.
Founders
Product
Problem
Developing effective therapies for complex diseases like autoimmune disorders and cancer is challenging due to interaction effects, toxicity, and high costs associated with multi-mechanism drugs. Current approaches struggle to efficiently identify and optimize non-toxic, bioactive molecules that can target multiple biological pathways simultaneously.
Solution
Interface Bio leverages natural products from commensal microbes to develop multi-targeted immunotherapies. The company's platform combines precision culturomics, targeted metabolomics, molecular engineering, and AI-driven optimization to mine natural product libraries. This approach generates non-toxic, bioactive molecules that target multiple biological pathways, offering a novel strategy for creating effective therapies for complex diseases. The platform aims to accelerate the discovery and development of next-generation immunotherapy assets with improved stability, potency, and safety profiles.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel immunotherapies for autoimmune disorders and cancer.
Features
- Builds libraries of microbial-derived natural products with high bioactivity potential.
- Screens chemical libraries curated from previously isolated microbial products and uncharacterized metabolites.
- Employs AI-guided search strategies to identify promising therapeutic candidates.
- Optimizes natural product molecules for enhanced efficacy and safety.
- Validates the therapeutic potential of identified compounds through rigorous testing.